This approach results in long‐term anti‐tumor immune memory in the mice.[15] Conversely, in a melanoma syngeneic model, combining anti‐CTLA‐4 with anti‐PD‐1 showed a strong synergistic anti‐tumor effect when CDK4/6i abemaciclib was administered sequentially after the immune checkpoint inhibitor.[3] Both studies suggest that sequential therapy might maximize the synergistic effect between CDK4/6i and ICB. The gene discussed is CTLA4; the disease is melanoma.